Obstructive sleep apnea is becoming more and more recognized as a health condition because it affects a considerable proportion of the population, in particular those with cardiovascular diseases, diabetes, and other chronic diseases ([@B1]). Sleep apnea can be classified as central if there is no effort or airflow (central apnea has a \<1% frequency of all apnea), obstructive if the respiratory effort is preserved and increased in the presence of partial or complete occlusion on the upper airway, and mixed if there is a combination of both central and obstructive apnea. Apnea results in intermittent hypoxia, recurrent arousals, changes in intrathoracic pressure, and changes in sleep architecture (reduction in rapid eye movement and deep sleep and an excess in stage 2 sleep). In some cases it is accompanied by excessive daytime sleepiness and disturbed sleep. It is diagnosed by an apnea-hypopnea index (AHI) of ≥5 episodes per hour during polysomnography; apnea is present in ∼1 in 4 individuals in the general adult population ([@B1]). Sleep apnea is associated with diabetes, hypertension, and cardiovascular disease. In recognition of this association, the International Diabetes Federation and the American Heart Association have both provided leadership in issuing recommendations for identifying and treating this condition ([@B2],[@B3]). The interrelation between sleep and the metabolic system is being increasingly recognized ([@B4],[@B5]).

Most of the studies on the epidemiology of sleep apnea are either cross-sectional or case-control studies. The prospective or longitudinal studies come from the 4-year follow-up of the Wisconsin Sleep Cohort Study ([@B6]) and the 5-year follow-up of two cohorts, the Cleveland Family Study ([@B7]) and the Sleep Heart Health Study ([@B8]). These three studies all used polysomnography to quantify sleep apnea, but the cohorts had an oversampling of individuals likely to have sleep apnea. In the 1981 Australian Busselton Health Survey of a general population ([@B9]), the incidence of snoring was studied over a 13-year follow-up; the risk factors were sex, obesity, and weight gain.

The main interest in the above studies was adiposity, and they showed that age, sex, and adiposity at baseline and anthropometric changes over follow-up are related to incident sleep apnea. Among other factors related to incident sleep-disordered breathing studied by Tishler et al. ([@B7]), only cholesterol levels were found to show a marginal association.

A recent cross-sectional study showed that both insulin sensitivity and insulin secretion were related to sleep-disordered breathing, as evaluated by the AHI during polysomnography, and the authors suggested that sleep-disordered breathing may lead to insulin resistance ([@B10]). In this report, we study, after accounting for adiposity, risk factors for incident observed sleep apnea in a population leaner than that in of most published reports with mean ± SD for BMI of 25.0 ± 3.8 kg/m^2^.

RESEARCH DESIGN AND METHODS
===========================

Participants were recruited into the study Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.) between 1994 and 1996. They were 30 to 65 years of age at recruitment and were consultants at Social Security Health Examination centers in the central western part of France.

We studied the 1,780 men and 1,785 women who were present at both the 3-year and the 9-year follow-up examinations and who, at both examinations, had BMI and waist circumference measured and responded to a question on whether they had observed sleep apnea, "Has someone said to you that you stop breathing during your sleep?" ([@B11]). The complete sleep questionnaire is shown in the online appendix (available at <http://care.diabetesjournals.org/cgi/content/full/dc09-1901/DC1>). Baseline date for this analysis is 1997--1999, 3 years after inclusion into the D.E.S.I.R. study.

At baseline and 6 years later, the clinical examinations followed the same protocol, with examinations by trained physicians and nurses. Two measures of blood pressure, using a mercury sphygmomanometer were taken with the participant in a supine position after a 5-min rest; mean values were used. Weight and height were measured in lightly clad participants, and BMI was calculated. The waist circumference, the smallest circumference between the lower ribs and the iliac crests, was also measured, as well as the neck circumference.

Smoking habits (current smoker or not), alcohol consumption (glasses per day of wine, beer, cider, and spirits, all transformed to grams per day), and degree of physical activity (people with little activity at home, at work, and in sporting activities were classified as physically inactive) were assessed using a self-administered questionnaire. All medications taken by participants were recorded.

We have defined observed apnea by a positive response to the question, "Has someone said to you that you stop breathing during your sleep?" The sleep questionnaire ([@B11]), as shown in the online appendix, included the Epworth Sleepiness Scale, which provides a measure of daytime sleepiness, that we study with the reference threshold of 10 or higher, which was derived in a general population ([@B12]).

All biochemical measurements were from one of four health center laboratories located in France at Blois, Chartres, La Riche, and Orléans. The interlaboratory variability for normal and pathological values was assessed monthly. Fasting plasma glucose, measured by the glucose-oxidase method, was applied to fluoro-oxalated plasma using a Technicon RA100 analyzer (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta device (Konelab, Evry, France). Total cholesterol, HDL cholesterol, and triglycerides were assayed with a DAX 24 (Bayer Diagnostics) or KONE analyzer (Konelab). LDL cholesterol was calculated from the Friedewald equation. A1C was determined by high-performance liquid chromatography (L9100 ion-exchange analyzer; Hitachi/Merck-VWR, Fontenay-sous-Bois, France) or an immunoassay (DCA 2000; Bayer Diagnostics). Insulin was quantified by microparticle enzyme immunoassay with an automated analyzer (IMX; Abbott, Rungis, France).

Diabetes was defined to include individuals treated for diabetes and those with a fasting plasma glucose ≥7.0 mmol/l. The homeostasis model assessment of insulin resistance (HOMA-IR) index was used as a surrogate measure of insulin resistance ([@B13]).

Statistical analysis
--------------------

Logarithms of triglycerides and insulin concentrations and of the HOMA-IR index have been used in statistical analyses. All data were analyzed using SAS (version 9.1; SAS Institute, Cary, NC). Data are presented as means ± SD and as percentages. Characteristics of those with and without observed apnea at baseline were compared by *t* or χ^2^ tests, stratified by sex.

Anthropometric characteristics of those with and without incident observed apnea at 6 years were compared by ANCOVA, with adjustment for baseline age, in participants without observed apnea at baseline. Factors measured at baseline were analyzed according to incident observed apnea by logistic regression, after verifying that the relations were linear, by including squared terms in the regression analyses; continuous variables were standardized according to sex, and relations were adjusted for age and waist circumference. Sex interactions were tested for each of these risk factors, and a combined analysis is presented, adjusted for age, waist, and sex. Results are presented as standardized odds ratios (ORs). Further, to test the homogeneity of the relation of insulin and the HOMA-IR index with incident observed apnea, interactions were tested across BMI classes: \<25, 25--30, and ≥30 kg/m^2^.

RESULTS
=======

At baseline, the prevalence of reported, observed apnea was 14% in men and 7% in women. Apnea was associated with aging and with higher BMI, waist circumference, and neck circumference ([Table 1](#T1){ref-type="table"}). After adjustment for age, all three anthropometric parameters---BMI, waist circumference, and neck circumference---were higher in those with observed apnea; the strongest relation was with waist circumference. There was no interaction between age and these anthropometric parameters. In both men and women, observed sleep apnea was associated with other sleep disorders, particularly snoring ([Table 1](#T1){ref-type="table"}). The Epworth Sleepiness Scale was associated with observed apnea only in men (*P* \< 0.01), with an average score of 6.9 in men with observed apnea and 6.2 in those without; there was no relation for women. Fasting glucose, A1C, insulin, the HOMA-IR index, and triglycerides were all significantly and positively associated with observed apnea in men (all *P* \< 0.006), whereas in women, there were fewer associations, and those significant were with total and LDL cholesterol and triglyceride concentrations (all *P* \< 0.04). Blood pressures were higher in those with apnea (all *P* \< 0.002). Neither smoking nor alcohol consumption showed a significant relation with observed apnea; men and women with observed apnea were more physically inactive than those without observed apnea (both *P* \< 0.007). Finally, in women 7.1% of those with observed apnea used hypnotics in contrast with 2.8% of those without observed apnea (*P* \< 0.01). All results were homogeneous across men and women, except for total and LDL cholesterol, for which the interactions with sex were significant.

###### 

Characteristics of participants at baseline, according to the presence of observed apnea during sleep: the D.E.S.I.R. study

                                                                Men          Women                                             
  ------------------------------------------------------------- ------------ ------------- -------- ------------- ------------ --------
  *n* (%)                                                       1,524 (86)   256 (14)               1,659 (93)    126 (7)      
  Age (years)                                                   50 ± 10      53 ± 10       0.0001   50 ± 10       54 ± 9       0.0001
  Diabetes                                                      4.7          11.7          0.0001   2.4           2.4          0.9
  Anthropometry                                                                                                                
      BMI (kg/m^2^)                                             25.5 ± 3.1   26.6 ± 3.6    0.0001   24.3 ± 4.2    25.8 ± 4.5   0.0003
      Waist circumference (cm)                                  90 ± 9       93 ± 10       0.0001   78 ± 11       82 ± 12      0.0001
      Neck circumference (cm)                                   40 ± 2       41 ± 3        0.0007   34 ± 2        35 ± 3       0.0001
  Sleep characteristics                                                                                                        
      Agitated sleep                                            16           29            0.0001   23            40           0.0001
      Difficulty to wake up                                     25           38            0.0001   42            60           0.0001
      Chronic unexplained fatigue                               10           18            0.0002   19            31           0.002
      Frequent wakening at night                                34           45            0.001    46            59           0.006
      Snoring                                                   66           89            0.0001   44            71           0.0001
      Epworth Sleepiness Scale score                            6.2 ± 4.0    6.9 ± 4.1     0.01     5.9 ± 4.2     5.7 ± 4.2    0.6
      Epworth Sleepiness Scale score ≥10                        20           27            0.02     20            21           0.8
  Biological parameters                                                                                                        
      Fasting glucose (mmol/l)                                  5.6 ± 0.9    5.8 ± 1.1     0.006    5.2 ± 0.7     5.2 ± 0.8    0.7
      A1C (%)                                                   5.5 ± 0.6    5.6 ± 0.6     0.002    5.4 ± 0.5     5.5 ± 0.6    0.07
      Insulin (pmol/l)[\*](#TF1-1){ref-type="table-fn"}         52 ± 32      62 ± 49       0.002    50 ± 34       52 ± 32      0.3
      HOMA-IR index[\*](#TF1-1){ref-type="table-fn"}            13.1 ± 9.9   16.9 ± 17.1   0.0006   11.9 ± 10.2   12.6 ± 8.2   0.2
      Total cholesterol (mmol/l)                                5.8 ± 0.9    5.7 ± 1.0     0.6      5.6 ± 0.9     5.8 ± 1.0    0.04
      HDL cholesterol (mmol/l)                                  1.4 ± 0.4    1.4 ± 0.4     0.4      1.7 ± 0.4     1.6 ± 0.4    0.5
      LDL cholesterol (mmol/l)                                  3.8 ± 0.8    3.7 ± 0.8     0.4      3.5 ± 0.9     3.6 ± 1.0    0.04
      Triglycerides (mmol/l)[\*](#TF1-1){ref-type="table-fn"}   1.4 ± 1.2    1.5 ± 1.0     0.006    1.0 ± 0.5     1.1 ± 0.6    0.04
  Blood pressure                                                                                                               
      Systolic (mmHg)                                           133 ± 15     137 ± 16      0.0002   126 ± 16      133 ± 18     0.0001
      Diastolic (mmHg)                                          80 ± 9       83 ± 10       0.0001   76 ± 9        77 ± 10      0.002
  Lifestyle factors                                                                                                            
      Smoking                                                   21           22            0.7      13            12           0.8
      Alcohol (g/day)                                                                                                          
  0                                                             11           12                     32            35           
  0--20 g/day                                                   26           25            0.8      44            37           0.2
  \>20 g/day                                                    63           64                     23            28           
      Physically inactive                                       27           36            0.001    26            37           0.007
  Drug treatments                                                                                                              
      Treatment by hypnotics                                    1.6          2.3           0.4      2.8           7.1          0.01

Data are means ± SD or %.

\*Logarithms taken for analysis.

The incidence of observed apnea was 14% in men and 6% in women, and men with incident observed apnea were 1 year older than those without; women were 4 years older ([Table 2](#T2){ref-type="table"}). In both men and women, higher baseline BMI and waist circumference were associated with incident apnea (all *P* \< 0.006), and in women only baseline neck circumference was also related with incident observed apnea, with a significant 0.6 cm larger neck circumference (*P* \< 0.01), in comparison to only 0.3 cm in men (*P* \< 0.1). Increases in BMI were associated with incident observed apnea in both men and women (both *P* \< 0.05), and an increase in neck circumference was also associated in women (*P* \< 0.0001).

###### 

Anthropometric characteristics in those without observed apnea at baseline, according to 6-year incident observed apnea, after adjustment for age at baseline: the D.E.S.I.R. study

                                No observed apnea at 6 years   Observed apnea at 6 years   *P* value
  ----------------------------- ------------------------------ --------------------------- -----------
  Men                                                                                      
      *n* (%)                   1,310 (86)                     214 (14)                    
      Baseline age (years)      50                             51                          
      Baseline BMI (kg/m^2^)    25.4                           26.0                        0.006
      Baseline waist (cm)       89.3                           91.2                        0.004
      Baseline neck (cm)        39.8                           40.1                        0.1
      Change in BMI (kg/m^2^)   0.57                           0.83                        0.02
      Change in waist (cm)      2.41                           2.75                        0.4
      Change in neck (cm)       0.42                           0.58                        0.2
  Women                                                                                    
      *n* (%)                   1,554 (14)                     105 (6)                     
      Baseline age (years)      50                             54                          
      Baseline BMI (kg/m^2^)    24.1                           26.2                        0.0001
      Baseline waist (cm)       77.4                           81.8                        0.0001
      Baseline neck (cm)        34.3                           34.9                        0.01
      Change in BMI (kg/m^2^)   0.86                           1.21                        0.05
      Change in waist (cm)      3.01                           4.16                        0.06
      Change in neck (cm)       0.40                           1.23                        0.0001

Data are means unless indicated otherwise.

Risk factors for incident apnea were studied separately in men and women ([Table 3](#T3){ref-type="table"}), but because there was no significant sex interaction for most of the risk factors (data not shown), men and women were combined for reporting the relation between cardiometabolic risk factors and incident observed apnea, after adjustment for age, waist circumference, and sex ([Table 3](#T3){ref-type="table"}). For total cholesterol and for alcohol intake, there was a sex interaction, with total cholesterol being predictive of apnea only in men (*P* \< 0.002); for alcohol, there was only a marginal relation in either sex. Combining men and women, insulin (*P* \< 0.0001), the HOMA-IR (*P* \< 0.0001) index and triglycerides (*P* \< 0.0009), smoking (*P* \< 0.006), and treatment by hypnotics (*P* \< 0.02) were related with incident observed apnea; diastolic blood pressure was close to showing statistical significance (*P* \< 0.06). In men, treatment by hypnotics was associated with a threefold increase in incident observed apnea.

###### 

Baseline cardiometabolic risk factors and their standardized ORs (95% CI) for incident observed apnea: the D.E.S.I.R. study

                                                                    Men                 *P* value   Women               *P* value   Men and women combined   *P* value
  ----------------------------------------------------------------- ------------------- ----------- ------------------- ----------- ------------------------ -----------
  Number of incident cases (*n*)/total participants studied (*N*)   214/1,524 (14)                  105/1,659 (6)                   319/3,183 (10)           
  Age[\*](#TF3-1){ref-type="table-fn"}                              1.12 (0.96--1.31)   0.1         1.32 (1.06--1.64)   0.01        1.18 (1.04--1.34)        0.008
  Waist circumference[†](#TF3-2){ref-type="table-fn"}               1.25 (1.07--1.46)   0.004       1.50 (1.24--1.80)   0.0001      1.34 (1.19--1.52)        0.0001
  Glucose                                                           1.01 (0.87--1.17)   0.8         1.14 (0.97--1.34)   0.1         1.07 (0.96--1.19)        0.2
  A1C                                                               1.04 (0.90--1.20)   0.6         1.04 (0.85--1.27)   0.7         1.05 (0.93--1.18)        0.4
  Insulin[‡](#TF3-3){ref-type="table-fn"}                           1.38 (1.15--1.65)   0.0004      1.19 (0.94--1.50)   0.1         1.31 (1.13--1.51)        0.0002
  HOMA-IR index[‡](#TF3-3){ref-type="table-fn"}                     1.35 (1.13--1.63)   0.0008      1.23 (0.97--1.54)   0.08        1.31 (1.13--1.51)        0.0002
  Diabetes[§](#TF3-4){ref-type="table-fn"}                          0.64 (0.30--1.35)   0.2         1.43 (0.56--3.64)   0.4         0.81 (0.45--1.46)        0.5
  Total cholesterol                                                 1.26 (1.08--1.46)   0.002       0.90 (0.72--1.12)   0.3         ---                      
  HDL cholesterol                                                   0.93 (0.79--1.10)   0.4         0.86 (0.68--1.09)   0.2         0.90 (0.79--1.03)        0.1
  LDL cholesterol                                                   1.18 (1.01--1.37)   0.03        0.91 (0.73--1.12)   0.4         1.10 (0.97--1.24)        0.1
  Triglycerides[‡](#TF3-3){ref-type="table-fn"}                     1.25 (1.07--1.47)   0.004       1.18 (0.94--1.47)   0.1         1.24 (1.09--1.41)        0.0009
  Systolic blood pressure                                           1.06 (0.90--1.24)   0.5         1.02 (0.81--1.28)   0.8         1.05 (0.91--1.19)        0.5
  Diastolic blood pressure                                          1.18 (1.01--1.38)   0.04        1.03 (0.83--1.29)   0.8         1.13 (0.99--1.28)        0.06
  Smoking                                                           1.53 (1.08--2.16)   0.02        1.48 (0.79--2.75)   0.2         1.52 (1.12--2.05)        0.006
  Alcohol                                                                                                                           ---                      
      0--20 vs. 0 g/day                                             0.58 (0.32--1.02)   0.06        1.01 (0.64--1.61)   0.9                                  
      \>20 vs. 0 g/day                                              0.92 (0.57--1.47)   0.07        0.62 (0.36--1.07)   0.1                                  
  Physical inactivity                                               1.17 (1.84--1.63)   0.3         1.03 (1.00--1.05)   0.7         1.11 (0.85--1.44)        0.4
  Treatment by hypnotics                                            3.54 (1.51--8.25)   0.003       1.11 (0.38--3.24)   0.8         2.13 (1.13--4.02)        0.02

Data are ORs (95% CI) unless indicated otherwise. Data are adjusted for age and waist circumference at baseline. The combined analyses have been also adjusted for sex.

\*Adjusted for waist circumference only.

†Adjusted for age only.

‡Logarithms taken for analysis.

§Diabetes defined by medication and/or fasting plasma glucose ≥7.0 mmol/l. ---, not reported as significant interaction between men and women.

The relation between insulin and the HOMA-IR index with incident observed apnea was homogeneous across BMI classes for both men and women. Thus, the observed relation does not seem to be the result of adiposity (data not shown).

The presence of observed apnea at baseline was not associated with an increase in adiposity over 6 years. The changes in waist circumference were 2.0 cm in men with baseline observed apnea and 2.2 cm in those without (*P* = 0.5); for women the corresponding changes were 1.6 and 2.8 cm (*P* = 0.4). Similarly, the changes in insulin were 4.8 and 11.4 pmol/l for men with and without baseline observed apnea (*P* = 0.6), and for women the changes were 5.1 and 7.2 pmol/l, respectively (*P* = 0.6). These results did not change after adjustment for age and waist circumference.

CONCLUSIONS
===========

As in other studies, this study also shows that adiposity was related to prevalent and incident apnea, and increases in adiposity over time were related to incident apnea. Our results pertain only to observed apnea. Other factors preceding incident observed apnea, after adjustment for age, waist circumference, and sex, were insulin, the HOMA-IR index, and triglyceride concentrations with standardized ORs of 1.31, 1.31, and 1.24, respectively; smoking also increased the risk of incident observed apnea by 50%. Whereas the use of hypnotics by women at baseline was related cross-sectionally with observed apnea, with no relation for men, the reverse was the case for incident observed apnea: use of baseline hypnotics had an OR of 3.54 in men, despite the fact that fewer than 2% of the men were treated with them.

The adverse effect of gaining weight on sleep-disordered breathing was clear from the 4-year Wisconsin Sleep Cohort Study ([@B6]): a 10% increase in weight, in comparison with a stable weight, was associated with a 32% higher increase in AHI and a sixfold risk of developing moderate to severe obstructive sleep apnea; a 10% decrease in weight was associated with a 26% decrease in the AHI. However, as indicated by Newman et al. ([@B8]), sleep apnea increases with aging, even in the weight-stable population. The Busselton Health Survey in Australia is one of the few studies in a general population in which sleep disorders have been prospectively examined over 15 years. In the 967 men and women, risk factors associated with the development of snoring were sex, baseline obesity, and weight gain ([@B9]); no biochemical measures were studied.

Other authors have shown cross-sectional relations between sleep-disordered breathing and glucose or diabetes ([@B14],[@B15]); however, to our knowledge, there are no other prospective studies with insulin, glucose, and diabetes as putative risk factors. In our study, neither baseline fasting glucose, nor A1C, nor the presence of diabetes was a risk factor for incident observed apnea. High insulin levels and high HOMA-IR index values were strongly related to incident observed apnea, particularly in men. This result was independent of the effects of the main risk factors for observed apnea (a large waist circumference, age, and sex).

We were not able to show the reverse relations, that the presence of observed apnea at baseline was associated with higher insulin levels or greater adiposity 6 years later. Thus, we believe that the high insulin levels seen with observed sleep apnea, precede this condition, rather than being caused by it. This analysis partly answers "the chicken or the egg" question posed with regard to abdominal fat and sleep apnea ([@B16]). It has been reported that women with polycystic ovary syndrome have a 30 times higher risk of having sleep-disordered breathing ([@B17]); insulin resistance seems to be the primary defect in these women, which is then followed by sleep-disordered breathing. There have been suggestions in the literature that the improvement in insulin sensitivity after treatment with continuous positive airway pressure is evidence that sleep-disordered breathing may be a causative risk factor for insulin resistance. However, there are as many positive as negative results on this relation in clinical investigations ([@B15]).

A possible mechanism for our observation that hyperinsulinemia and insulin resistance precede observed apnea is that in obesity, the level of pharyngeal dilator muscle activity may be diminished in the presence of insulin or insulin resistance, just as the alteration in arterial muscle tone that is well recognized in vascular disease ([@B18]). An alternative or additional mechanism may be the inflammation associated with hyperinsulinemia, insulin resistance, and abdominal adiposity, preceding sleep apnea ([@B15]).

The cross-sectional associations that have been shown in the literature among apnea, cigarette smoking, and alcohol consumption ([@B14]) were not seen in our study, but we found that smokers had a 50% higher risk of incident observed apnea than nonsmokers and that there was a trend for higher alcohol intake in men only. Physical inactivity has been little studied in relation to apnea; in our cross-sectional study, physical inactivity was more frequent in men and women with than without observed apnea at baseline, but it was not associated with incident observed apnea.

The strength of our study is the large cohort, drawn from a general population, with 6 years of follow-up. However, we must acknowledge the main limitation of our study: the lack of recorded polysomnographic data. Our measure of "observed apnea," as reported by the participants in our study, is a crude and nonobjective measure. A polysomnographic recording was performed in 225 men and women from this cohort: 8 men and 2 women reported that they had observed apnea; 6 of these men and both women had an AHI ≥15 and all had an AHI ≥10 (data not published). Furthermore, an argument for the use of observed apnea is the observation that in obese individuals presenting for obesity surgery, reported observed apnea was the only symptom related to obstructive sleep apnea ([@B19]). These two elements provide some support for the use of our question on observed apnea. Reported apnea, observed by another person, is probably the information that a general practitioner would have to make a referral, and thus it is a simple method to screen people requiring further investigation. Another limitation for the interpretation of our study is that an individual must have a sleeping partner for apnea to be observed; thus, our estimates may be underestimates of the actual frequency, as only individuals with severe apnea would be able to report their own. However, the frequency of apnea in those living or not as a couple was 11 and 9%, i.e., almost identical, and their characteristics were similar except that there were more women who reported that they were living alone. We do not have a direct measure of insulin resistance, and we have used both insulin and the HOMA-IR index as surrogate measures. However, hyperinsulinemia and insulin resistance do not always occur together ([@B20],[@B21]), and the HOMA-IR index and insulin have similar correlations with clamp-measured insulin sensitivity in a nondiabetic population (Spearman correlation coefficients; −0.505 and 0.525, respectively, from the Relationship between Insulin Sensitivity and Cardiovascular Disease \[RISC\] study) ([@B20],[@B21]).

Adiposity was strongly related to incident apnea, but after accounting for this relation, the risk of observed apnea also increased with increasing insulin levels and with an increasing HOMA-IR index. This is the first report that has been able to show that hyperinsulinemia and an insulin resistance index are predictive of later apnea, albeit observed apnea, after accounting for adiposity and changes in adiposity. Limiting weight gain is the simplest but probably the hardest-to-achieve preventive strategy for sleep apnea. Increasing physical activity and limiting sedentary behavior could play a role in increasing insulin sensitivity ([@B22]) and decreasing the risk for apnea.
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